Valuation: Bolt Biotherapeutics, Inc.

Market Cap 6.28M 5.39M 5.03M 4.62M 8.68M 600M 8.82M 59.35M 23.24M 301M 23.58M 23.07M 995M P/E 2026 *
-0.14x
P/E 2027 * -0.16x
Enterprise Value 6.28M 5.39M 5.03M 4.62M 8.68M 600M 8.82M 59.35M 23.24M 301M 23.58M 23.07M 995M EV / Sales 2026 *
31.4x
EV / Sales 2027 * 1.79x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+2.60%
1 week-5.51%
Current month-18.30%
1 month-26.24%
3 months-30.93%
6 months-36.45%
Current year-40.38%
1 week 3.16
Extreme 3.16
3.74
1 month 3.13
Extreme 3.13
4.34
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
385.7
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 14/05/2024
Chief Executive Officer 55 14/05/2024
Chief Operating Officer 61 14/05/2024
Director TitleAgeSince
Director/Board Member 64 30/11/2020
Director/Board Member 55 14/05/2024
Chairman 56 03/09/2024
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Chairman

5,000 0.2602%
28/01/26 Free

Chief Operating Officer

10,000 0.5210%
28/01/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+2.60%-5.51%-31.85%-85.83% 6.28M
-1.90%+3.12%+81.70%+110.88% 72.21B
+0.02%+15.96%+55.33%+91.80% 63.98B
-0.48%-1.22%+2.71%+501.29% 28.53B
+3.63%+8.57%+62.12%+24.72% 25.07B
-4.98%+21.98%+1.54%+2.50% 28.42B
-0.49%+5.78%+38.78%-14.15% 20.04B
0.00%-2.78%+247.46%+423.83% 18.19B
+1.81%+1.43%+23.67%+527.06% 15.96B
-0.46%+7.96%+44.96%+157.77% 13.48B
Average +0.05%+4.60%+52.64%+173.99% 28.59B
Weighted average by Cap. -0.62%+6.69%+60.80%+163.84%

Financials

2026 *2027 *
Net sales 200K 172K 160K 147K 276K 19.12M 281K 1.89M 740K 9.59M 751K 735K 31.7M 3.5M 3M 2.8M 2.57M 4.84M 335M 4.92M 33.08M 12.95M 168M 13.14M 12.86M 555M
Net income -47.4M -40.66M -37.97M -34.83M -65.5M -4.53B -66.58M -448M -175M -2.27B -178M -174M -7.51B -47.5M -40.75M -38.05M -34.91M -65.64M -4.54B -66.72M -449M -176M -2.28B -178M -174M -7.53B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
19/08/26 US$3.260 +2.60% 21,148
18/08/26 US$3.177 -0.71% 7,335
17/08/26 US$3.200 -4.48% 24,576
14/08/26 US$3.350 +4.36% 15,961
13/08/26 US$3.210 -6.96% 28,389
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.260USD
Average target price
29.00USD
Spread / Average Target
+789.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock